TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06116110: Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Sponsor: Miltenyi Biomedicine GmbH · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,079,000

Rescue Site Savings

+$1,386,000

Unlock Full NCT06116110 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06116110 Rescue Dossier →